Life Science News

Toronto Stock Exchange, TSX Venture Exchange  TMX Group today announced its financing activity on Toronto Stock Exchange and TSX Venture Exchange for December 2021 . TSX welcomed nine new issuers in December 2021 compared with 25 in the previous month and 10 in December 2020 . The new listings were four exchange traded funds, two mining companies, two life sciences companies and one technology company. Total ...

Toronto Stock Exchange, TSX Venture Exchange

 TMX Group today announced its financing activity on Toronto Stock Exchange and TSX Venture Exchange for December 2021 .

TSX welcomed nine new issuers in December 2021 , compared with 25 in the previous month and 10 in December 2020 . The new listings were four exchange traded funds, two mining companies, two life sciences companies and one technology company. Total financings raised in December 2021 decreased 52% compared to the previous month, and were down 35% compared to December 2020 . The total number of financings in December 2021 was 56, compared with 60 the previous month and 53 in December 2020 .

For additional data relating to the number of transactions billed for TSX, please click on the following link: https://www.tmx.com/resource/en/440

TSXV welcomed 14 new issuers in December 2021 , compared with 16 in the previous month and eight in December 2020 . The new listings were 11 capital pool companies and three mining companies. Total financings raised in December 2021 increased 2% compared to the previous month, but were down 5% compared to December 2020 . There were 165 financings in December 2021 , compared with 138 in the previous month and 177 in December 2020 .

TMX Group consolidated trading statistics for December 2021 can be viewed at www.tmx.com .

Toronto Stock Exchange


December 2021

November 2021

December 2020

Issuers Listed

1,749

1,751

1,642

New Issuers Listed

9

25

10

IPOs

5

21

8

Graduates from TSXV

4

3

2

Issues Listed

2,425

2,423

2,293

IPO Financings Raised

$67,250,050

$2,328,258,567

$339,028,246

Secondary Financings Raised

$1,247,278,543

$2,479,445,842

$3,479,516,201

Supplemental Financings Raised

$1,190,475,684

$436,147,496

$47,308,800

Total Financings Raised

$2,505,004,277

$5,243,851,905

$3,865,853,247

Total Number of Financings

56

60

53

Market Cap Listed Issues

$4,223,871,393,563

$4,098,383,716,196

$3,398,550,102,622

Year-to-date Statistics


2021

2020

% change

New Issuers Listed

213

170

+25.3

IPOs

157

140

+12.1

Graduates from TSXV

36

20

+80.0

IPO Financings Raised

$10,487,796,183

$6,759,887,738

+55.1

Secondary Financings Raised

$28,374,208,875

$27,199,147,749

+4.3

Supplemental Financings Raised

$7,054,778,977

$2,220,900,538

+217.7

Total Financings Raised

$45,916,784,035

$36,179,936,025

+26.9

Total Number of Financings

641

533

+20.3

Market Cap Listed Issues

$4,223,871,393,563

$3,398,550,102,622

+24.3

TSX Venture Exchange **


December 2021

November 2021

December 2020

Issuers Listed

1,892

1,899

1,889

New Issuers Listed

14

16

8

IPOs

13

9

5

Graduates to TSX

4

3

2

Issues Listed

2,000

2,011

1,974

IPO Financings Raised

$10,012,922

$70,656,617

$12,042,642

Secondary Financings Raised (1)

$235,851,660

$177,743,941

$370,556,898

Supplemental Financings Raised

$665,389,223

$644,211,413

$576,022,238

Total Financings Raised

$911,253,805

$892,611,971

$958,621,778

Total Number of Financings

165

138

177

Market Cap Listed Issues

$102,467,123,398

$101,455,114,372*

$78,362,951,154

Year-to-date Statistics


2021

2020

% Change

New Issuers Listed

147

63

+133.3

IPOs

101

39

+159.0

Graduates to TSX

36

20

+80.0

IPO Financings Raised

$269,665,407

$213,018,283

+26.6

Secondary Financings Raised (1)

$3,621,917,540

$1,879,583,265

+92.7

Supplemental Financings Raised

$7,138,371,483

$4,570,886,951

+56.2

Total Financings Raised

$11,029,954,430

$6,663,488,499

+65.5

Total Number of Financings

1,684

1,717

-1.9

Market Cap Listed Issues

$102,467,123,398

$78,362,951,154

+30.8


*correction


**Includes NEX (not applicable to New Issuers Listed, IPOs and IPO Financings Raised)


(1)      Secondary financings include prospectus offerings on both a  treasury and secondary basis

TMX Group does not guarantee either the completeness or the accuracy of this information. The information contained in this media release is provided for informational purposes only and you agree not to rely upon the information contained in this media release for any trading, business, or financial purposes.  By using this media release, you expressly agree to the condition that TMX Group assumes no liability or responsibility for any errors or inaccuracies in this media release.

TMX Group welcomes the following companies that listed during December 2021 :

Toronto Stock Exchange

Issuer Name

Company Symbol

Aclara Resources Inc.

ARA

BMO Money Market Fund

ZMMK

BriaCell Therapeutics Corp.

BCT

Fidelity Advantage Bitcoin ETF

FBTC & FBTC.U

Givex Information Technology Group Limited

GIVX

Horizons GX Cybersecurity Index ETF

HBUG

Horizons GX Telemedicine and Digital Health Index ETF

HDOC

Numinus Wellness Inc.

NUMI

Orezone Gold Corporation

ORE

TSX Venture Exchange

Issuer Name

Company Symbol

ECC Ventures 5 Corp.

ECCV.P

ECC Ventures 6 Corp.

ECCS.P

EV Nickel Inc.

EVNI

Fairplay Ventures Inc.

FPY.P

Fountainhall Capital Corp.

FUN.P

Gold Basin Resources Corporation

GXX

Harmony Acquisitions Corp.

MONY.P

New Media Capital 2.0 Inc.

NEME.P

PC 1 CORP.

PCAA.P

Roshni Capital Inc.

ROSH.P

Rumbu Holdings Ltd.

RMB.P

Rupert's Crossing Capital Inc.

RUCC.P

Taura Gold Inc.

TORA

Wittering Capital Corp.

WITT.P

About TMX Group (TSX:X)

TMX Group operates global markets, and builds digital communities and analytic solutions that facilitate the funding, growth and success of businesses, traders and investors. TMX Group's key operations include Toronto Stock Exchange , TSX Venture Exchange , TSX Alpha Exchange , The Canadian Depository for Securities , Montréal Exchange , Canadian Derivatives Clearing Corporation , and Trayport which provide listing markets, trading markets, clearing facilities, depository services, technology solutions, data products and other services to the global financial community. TMX Group is headquartered in Toronto and operates offices across North America (Montréal, Calgary , Vancouver and New York ), as well as in key international markets including London and Singapore . For more information about TMX Group, visit our website at www.tmx.com . Follow TMX Group on Twitter: @TMXGroup .

SOURCE TMX Group Limited

Cision View original content: http://www.newswire.ca/en/releases/archive/January2022/11/c2893.html

News Provided by Canada Newswire via QuoteMedia

BCT:CA
BriaCell

BriaCell

Overview

BriaCell Therapeutics Corp. (NASDAQ:BCTX, BCTXW, TSX:BCT) is a biotechnology company with a mission to develop innovative immunotherapies for treating cancer and infectious diseases.

At the forefront of cancer treatments, immunotherapies boost the ability of the body's own cancer-fighting cells to destroy cancerous tumors. Immunotherapies also have low-toxicity, making it easier for patients to undergo treatment. Most importantly, they may offer better efficacy and less chance of recurrence for many cancer patients. In a report released by Research and Markets, the global immuno-oncology market is expected to reach $100 billion by 2022, and BriaCell continues to uncover opportunities in this space with its innovative technologies.

BriaCell's lead candidate, Bria-IMT™, is an immunotherapy currently being developed to treat advanced breast cancer, which is the expected cause of approximately 43,000 deaths in the US in 2021. Bria-IMT™ recently achieved positive proof of concept, showing outstanding safety and efficacy data. Importantly, preliminary efficacy data was similar or superior to those of other approved breast cancer drugs when they were at a similar stage of clinical development.

BriaCell currently has a non-exclusive clinical trial collaboration with Incyte Corporation (NASDAQ:INCY) to evaluate the effects of combinations of novel clinical candidates. Under the agreement, Incyte and BriaCell will be evaluating novel combinations of compounds from Incyte's development portfolio with BriaCell's drug candidates in advanced breast cancer patients.

BriaCell has been dosing patients in a Phase I/IIa clinical trial of Bria-IMT™ in combination with the immunotherapy development candidates retifanlimab, an anti-PD-1 antibody, and is planned to also combine with epacadostat, an orally bioavailable small-molecule inhibitor of indoleamine 2,3-dioxygenase 1 (both provided by Incyte). The combination study is listed in ClinicalTrials.gov as NCT03328026.

BriaCell is also developing Bria-OTS™, an off-the-shelf personalized immunotherapy, for advanced breast cancer. Bria-OTS™ immunotherapy treatments are personalized to match the patient without the need for personalized manufacturing. Bria-OTS™, which is expected to match over 99 percent of the patient population, is designed to produce a potent and selective immune response against the cancer of each patient while eliminating the time, expense and complex manufacturing logistics associated with other personalized immunotherapies.

In November 2020, BriaCell announced a Cooperative Research and Development Agreement with the National Cancer Institute (NCI, Center for Cancer Research), part of the National Institutes of Health, to investigate novel off-the-shelf personalized therapeutics for cancer.

BriaCell's management team is comprised of a team of experienced industry leaders involved in the approval of dozens of drugs.

BriaCell Therapeutics' Company Highlights

BriaCell has truly emerged in the last 13 months:

  • April 2021: Closing of Over-Allotment Option in Connection with U.S. Public Offering, Bringing Total Gross Proceeds to US$28.7 Mil
  • February 2021: BriaCell Announces Closing of US$25 Mil Public Offering
  • November 2020: BriaCell Announces Collaboration with the NCI
  • October 2020: Survival Data: 13.3 months vs. 7.2-9.8 months
  • January 13, 2020: Remarkable Responder Update
  • January 9, 2020: Additional 'Biomarker' identified; Possible predictor of high-responding patients
  • October 7, 2019: First patient dosed under Incyte Corporation collaboration

The Cancer Immunotherapy Space

There are a number of challenges that cancer immunotherapy treatments face. Approved immunotherapies work in 20 to 30 percent of patients. They depend on the patient's weakened immune system and, in some cases can cause autoimmune disease.

Other challenges include the lack of effectiveness of cancer immunotherapies to treat some solid tumors or blood cancers since they only work in certain types of cancer and not in others. Additionally, newly developed effective personalized immunotherapies such as PROVENGE® and CAR-T need to be individually manufactured for each patient. This means a complex and time-consuming manufacturing process, which is extremely expensive and might make the therapies commercially unsuccessful.

In response to these challenges, BriaCell is developing Bria-OTS™, an off-the-shelf personalized immunotherapy, for advanced breast cancer, which has been estimated to be the cause of about 43,000 deaths in the US in 2021.

The off-the-shelf approach means that the treatments are pre-manufactured and the patient will be able to receive her or his personalized, targeted treatment using an easy and common HLA test on her or his saliva sample. This approach is quick, and relatively inexpensive, and avoids the complex manufacturing process associated with other personalized immunotherapy treatments. This approach is the first of its kind for advanced breast cancer.

Bria-IMT™

Bria-IMT™, BriaCell's lead product candidate, is derived from a specific breast cancer cell line. It is genetically engineered to release granulocyte-macrophage colony-stimulating factor (GM-CSF), a substance that activates the immune system. BriaCell believes that Bria-IMT™ helps the body to stimulate cancer-fighting T-cells, cells that directly attack tumor cells, and B-cells that produce anti-tumor antibodies.

Proof-of-concept clinical trials

The first clinical trial used the original unmodified breast cancer cell line, with low dose cyclophosphamide and GM-CSF to boost the immune response. Fourteen patients were treated and produced impressive results, including no severe drug-related side-effects and a median survival rate in patients after treatment of about twice what was expected.

The second clinical trial used Bria-IMT™ (i.e. the original cell line – modified to produce GM-CSF) along with low dose cyclophosphamide and interferon-alpha in four advanced-stage cancer patients. The treatment was tolerated very well with few side effects. The median overall survival was much longer than expected. The study also had one patient that responded extremely well to the treatment with an approximately 90 percent tumor reduction in breast cancer as well as disappearance of the cancer from the lungs and soft tissues.

Source: BriaCell Therapeutics Corp.

After the treatment stopped, as required by the study, the patient's breast cancer returned and had spread to the patient's brain, lungs and other sites. Importantly, the patient was treated again with Bria-IMT™ and the tumors were reduced at multiple sites, even in the brain. This patient-matched Bria-IMT™ for HLA genes which are used to match patients to tissues in tissue transplantation (e.g. for kidney transplants).

Recent clinical findings (Phase I/IIa proof-of-concept study with Bria-IMT™: 2017 to 2018)

BriaCell completed a Phase IIa study of Bria-IMT™ in advanced breast cancer in 23 patients that were heavily pre-treated (listed in ClinicalTrials.gov as NCT03066947) and released their initial data in September 2018. To date, Bria-IMT™ treatment has been safe with several instances of tumor reduction observed in certain patients sharing a key biomarker (HLA match) with Bria-IMT™. The treatment was safe and well-tolerated. Most importantly, initial efficacy data was similar or superior to those of other advanced or approved drugs for breast cancer when they were at a similar stage of clinical development.

Based on the recent findings related to the mechanism of action of Bria-IMT™, and the potential to produce intensified anti-tumor activity when used in combination with certain drugs, the company is now conducting the combination study of Bria-IMT™ with retifanlimab and epacadostat. The combination study is listed in ClinicalTrials.gov as NCT03328026.

Immune checkpoint inhibitors such as anti-PD-1 including pembrolizumab (KEYTRUDA®; manufactured by Merck & Co., Inc.) and, more recently, Incyte's retifanlimab (under a corporate collaboration with Incyte Corporation) , are designed to neutralize immune suppression in cancer patients. The significance of immune checkpoints has been recognized by the Nobel committee by awarding Drs. Honjo and Allison with the 2018 Nobel Prize in Physiology or Medicine. BriaCell believes that Bria-IMT™ can exert additive or synergistic tumor-directed effects with checkpoint inhibitors like KEYTRUDA®. Initial safety data for the combined approach shows that it is very safe and well-tolerated by patients. Early efficacy data for the first eleven advanced breast cancer patients dosed with Bria-IMT™ in combination with KEYTRUDA® suggested strong additive or synergistic effects on tumor regression (shrinkage).

BriaCell hypothesizes that checkpoint inhibitors act by “awakening" a component of the immune system, while Bria-IMT™ “puts the foot on the gas" of the immune system, which may lead to more powerful anti-tumor activity.

BriaCell Therapeutics' Collaboration with Incyte Corporation

In April 2019, BriaCell and Incyte Corporation formed a non-exclusive clinical trial collaboration to evaluate the effects of combinations of novel clinical candidates. Under the agreement, Incyte and BriaCell plan to evaluate novel combinations of compounds from Incyte's development portfolio with Bria-IMT™ in advanced breast cancer patients.

BriaCell initiated dosing patients with advanced breast cancer in its Phase I/IIa clinical study for Bria-IMT™ in combination with Incyte's retifanlimab and epacadostat. The goal of the program is to remove cancer-induced suppression of the immune system (taking the “foot off the breaks" that cancer puts on the immune system) and stimulating an immune response with the Bria-IMT™, putting the “foot on the gas". This is expected to allow the immune system to attack the cancer in a targeted way with the help of Bria-IMT™. The combination study is listed in ClinicalTrials.gov as NCT03328026.

BriaDX™

BriaCell has developed a companion diagnostic test that would allow a physician to prepare a personalized pre-made treatment for each patient based on the presence of certain biomarkers (HLA type). Testing is simple and done on the patient's saliva.

This diagnostic test may be used in future clinical trials to speed up the clinical development of Bria-IMT™ and will be used in trials of Bria-OTS™.

Bria-OTS™

The Bria-OTS™ treatment is based on pre-manufactured immunotherapies – each containing a specific HLA type – which can be selectively administered to patients based on the patient's HLA type. BriaCell is developing 15 unique HLA types that will allow for the treatment of over 99 percent of advanced-staged breast cancer patients. This approach provides customized cancer immunotherapy for each individual patient that doesn't require personalized manufacturing.

Source: BriaCell Therapeutics Corp.

A simple diagnostic test, BriaDX™, will determine the appropriate off-the-shelf immunotherapy for each patient. Based on the results, one or two pre-made Bria-OTS™ immunotherapy cell lines will be selected to be administered to the patient. Thus, Bria-OTS™ is expected to provide the patient with fast, inexpensive, safe and effective personalized cancer immunotherapy treatment that can be ordered readily.

BriaCell Therapeutics' Small Molecule Program

BriaCell's small molecule program includes the development of novel, selective protein kinase C delta (PKCδ) inhibitors which have shown potent activity in a number of pre-clinical models of several different cancer indications as well as fibrotic diseases. Protein kinase C delta (PKCδ) inhibitors may provide another shot on goal besides a potential partnership opportunity.

BriaCell Therapeutics' Management Team

William V. Williams, MD, FACP, President & CEO, Director

  • Former VP, Exploratory Development, Incyte Corporation
  • Former VP, Experimental Medicine, GlaxoSmithKline
  • Former Head, Rheumatology Research, University of Pennsylvania
  • Extensive drug development experience

Gadi Levin, CA, MBA – CFO and Corporate Secretary

  • CFO of Labstyle Innovations Ltd
  • VP of Finance for two Israeli investment houses in the fields of private equity, hedge funds and real estate
  • Financial Consultant, various firms
  • Accountant, Arthur Andersen

BriaCell Therapeutics' Board of Directors

Jamieson Bondarenko, CFA, CMT, Chairman of the Board

  • Previously Principal and Managing Director of the Equity Capital Markets group of Eight Capital
  • Previously several positions at Dundee Securities Ltd., including Managing Director, Director, Vice President and Associate

Vaughn Embro-Pantalony, MBA, FCPA, FCMA, CDir, ACC, Director

  • Current: Chair, Board of Directors, Soricimed Biopharma Inc.
  • Board and Audit Committee Member, Microbix Biosystems Inc.
  • VP, Finance & CFO, Teva Novopharm Limited
  • VP, Finance & Administration, Bayer Healthcare
  • Director, Finance and Administration & CFO, Zeneca Pharma Inc.

Marc Lustig — Director

  • Investor, entrepreneur, and corporate finance veteran with a deep understanding of the life sciences industry, including biotechnology and pharmaceuticals, as well as the legal cannabis industry.
  • Holds MSc and MBA degrees from McGill University and his professional experience includes working at Merck & Co.,
  • His capital markets career includes roles in biotech equity research, corporate finance and as Head of Capital Markets.
  • Founder and CEO of Origin House where he currently serves as a director.
  • Director of a number of public companies, and founded the Lustig Family Medical Cannabis Research & Care Fund of the Cedars Cancer Foundation that provides cannabis to palliative cancer patients.

Martin Schmieg, CPA, Director

  • Current: CEO, ClearIT, LLC
  • CFO: Sirna Therapeutics, Inc., & Isolagen, Inc.
  • CEO, Freedom-2, Inc. (now PharmaCyte, Inc.)
  • Advisor, Caladrius Biosciences, Inc., Beckman Coulter Genomics, Calimmune, Inc., Cryoport, Inc., Vetbiologics, a division of U.S. Stem Cell, Inc., Sapientia Pharmaceuticals, Inc., & Rokk3r Labs, LLC

Rebecca A. Taub, MD, Director

  • Current: CMO & EVP, Director, Founder, Madrigal Pharmaceuticals
  • Senior VP, VIA Pharmaceuticals
  • VP of Research, Metabolic Diseases, Hoffmann-La Roche Company
  • Executive Director, Bristol-Myers Squibb
  • Executive Director, Dupont Pharmaceuticals
  • Professor of Genetics and Medicine, University of Pennsylvania

Jane Gross, Ph.D., Director

  • Chief Scientific Officer and SVP, Research and Non-Clinical Development at Aptevo Therapeutics (Nasdaq: APVO)
  • VP, Applied Research and Non-Clinical Development at Emergent BioSolutions (NYSE: EBS)
  • VP, Immunology Research at ZymoGenetics
  • Independent Director for aTyr Pharmaceuticals (Nasdaq: LIFE)

Suzanne Ostrand-Rosenberg, Ph.D. - Advisor

  • 40 years of experience leading investigations focused on the immune system's response to cancer.
  • Robert & Jane Meyerhoff Professor of Biochemistry, Emeritus
  • Professor of Biological Sciences, Emeritus, University of Maryland Baltimore County, Baltimore, MD, and has been working with the University since 1977.
  • Adjunct Professor of Pathology, Huntsman Cancer Institute (HCI), University of Utah, Salt Lake City, UT, in 2018.

BriaCell Therapeutics' Management Team

William V. Williams, MD, FRCP, President & CEO

  • Seasoned biopharmaceutical executive with over 35 years of industry and academic expertise, including significant clinical management in multinational pharmaceutical companies.
  • Served as VP of Exploratory Development at Incyte Corporation from 2005 – 2016.
  • Facilitated entry of over 20 compounds into the clinic, including approvals for ruxolitinib (Jakafi) and baricitinib (Olumiant).
  • Responsible for establishing proof-of-concept in several therapeutic areas
  • Involved in numerous new drug applications (NDAs) for therapeutics that achieved marketing authorization

Gadi Levin, CA, MBA, CFO & Corporate Secretary

  • Appointed as BriaCell Therapeutics Corp.'s Chief Financial Officer in February 2016.
  • Acted as Chief Financial Officer of Labstyle Innovations Ltd, a biotechnology company focused on diabetes.
  • Served as the Vice President of Finance and Chief Financial Officer for two Israeli investment houses in the fields of private equity, hedge funds and real estate (2008 to 2009 and 2010, respectively).

Miguel A. Lopez-Lago, Ph.D., Senior Director, Research and Development

  • Working as a cancer scientist at Memorial Sloan-Kettering Cancer Center, New York (MSKCC).
  • Investigated various aspects of tumor biology, including the development of targeted therapies for Mesothelioma and the characterization of the biological mechanisms underlying cancer metastasis.
  • Interested in the study of the tumor immune-microenvironment and in the development of immunotherapies for thoracic cancers using chimeric antigen receptor (CAR) T cell technologies.
  • Since 2013, Dr. Lopez-Lago has been working as Senior Research Scientist at MSKCC. Dr. Lopez-Lago received his Bachelor of Science in Bio-Sciences and his doctorate in Molecular Biology from Santiago of Compostela University, Spain.
Keep reading... Show less
TSXV:BCT

BriaCell Presents Clinical and Scientific Findings at the Annual Symposium of Society of Surgical Oncology 2020

Preliminary safety and efficacy data are being presented today from the clinical trials of Bria-IMT™ in combination with immune checkpoint (PD-1) inhibitors in advanced breast cancer patients.

  • Clinical responses and disease control—without serious side effects—in heavily pre-treated patients with metastatic breast cancer seen with lead candidate, Bria-IMT™, in combination with pembrolizumab (KEYTRUDA®; manufactured by Merck & Co., Inc.), a PD-1 inhibitor.
  • Higher levels of immune system activation were directly related to higher incidences of tumor reduction and higher rates of disease control and clinical benefit in patients with advanced breast cancer.

BriaCell Therapeutics Corp. (“BriaCell” or the “Company”) (TSXV:BCT) (OTCQB:BCTXF), a clinical-stage biotechnology company specializing in targeted immunotherapy for advanced breast cancer, is announcing the results of clinical studies with its lead product candidate, Bria-IMT™, summarized in a poster session during the SSO 2020 International Conference on Surgical Cancer Care™, a virtual event held in the evenings of August 17-18, 2020. The patient data summarized and discussed belong to previously-disclosed patients (i.e., no incremental numbers enrolled).

Keep reading... Show less
OTC:BCTXF

BriaCell Announces Presentation and Abstract Publication at 2020 American Society of Clinical Oncology (ASCO) Meeting

BriaCell Therapeutics Corp. (“BriaCell” or the “Company”) (TSXV:BCT) (OTCQB:BCTXF), a clinical-stage biotechnology company specializing in targeted immunotherapy for advanced breast cancer, announces the publication of its abstract in the ASCO Meeting Library — available in the Journal of Clinical Oncology by May 26, 2020. The Company will present at the 2020 ASCO Annual Meeting, a virtual event held during the dates of the originally planned in-person Annual Meeting (May 29-June 2, 2020). The ASCO Annual Meeting represents the world’s largest gathering of oncology physicians, biotechnology executives, researchers, and investment analysts to discuss cutting-edge clinical research and therapeutics in oncology.

Dr. Bill Williams, BriaCell’s President & CEO, and Dr. Charles Wiseman, BriaCell’s Scientific Founder and Director, will present clinical data and pathological findings from the Phase I/IIa studies of Bria-IMT™ alone or in combination with checkpoint inhibitors in advanced breast cancer patients.

Keep reading... Show less
OTC:BCTXF

BriaCell Continues Business and Clinical Operations During COVID-19 Pandemic

  • Phase I/IIa clinical study of BriaCell’s lead candidate, Bria-IMT™, for breast cancer treatment, with Incyte Corporation’s immune checkpoint inhibitor, INCMGA00012, is ongoing and recruiting patients amidst the COVID-19 pandemic.
  • BriaCell is currently evaluating a number of business strategies to develop its potential treatments for breast cancer on its own or in partnership.
  • Clinical and pathological findings of Bria-IMT™, alone or in combination with checkpoint inhibitors, KEYTRUDA® and INCMGA00012, in advanced breast cancer will be presented at upcoming conferences.

BriaCell Therapeutics Corp. (“BriaCell” or the “Company”) (TSXV:BCT) (OTCQB:BCTXF), a clinical-stage biotechnology company specializing in targeted immunotherapy for advanced breast cancer, announces that the Phase I/IIa clinical study of Bria-IMT™, for breast cancer treatment, with Incyte Corporation’s immune checkpoint inhibitor, INCMGA00012, is ongoing and recruiting patients amidst the COVID-19 pandemic. Further, BriaCell is currently evaluating a number of business strategies to develop its potential treatments for breast cancer on its own or in partnership. BriaCell will be presenting the clinical and pathological findings of Bria-IMT™, alone or in combination with checkpoint inhibitors, KEYTRUDA® and INCMGA00012, in advanced breast cancer will be presented at upcoming conferences including 2020 American Society of Clinical Oncology (ASCO) Meeting (May 29-Jun 2, 2020), and American Association for Cancer Research (AACR) Annual Meeting in August 2020.

“We are committed to develop treatment solutions for advanced breast cancer patients with no effective treatment options and understand that continuation of our clinical studies during these unprecedented times is critical for our patients. We are grateful to our clinical team for having made the task possible,” said Dr. Bill Williams, BriaCell’s President & CEO.

Keep reading... Show less
OTC:BCTXF

BriaCell Files Patent Application for Novel Therapeutics for Cancer

BriaCell Therapeutics Corp. (“BriaCell” or the “Company”) (TSXV:BCT) (OTCQB:BCTXF), a clinical-stage biotechnology company specializing in targeted immunotherapy for advanced breast cancer, announces that it has filed a provisional patent application with the U.S. Patent and Trademark Office (USPTO) outlining the development and use of novel therapeutics (i.e. multi-specific binding reagents) that activate immune cells to selectively destroy the cancer cells or to selectively block cancer cells from inactivating immune cells.

The patent application, entitled “METHODS FOR INDUCING AND ENHANCING ANTI-CANCER IMMUNE RESPONSES USING NOVEL MOLECULAR CONSTRUCTS”, outlines the development and use of multi-specific binding reagents that simultaneously bind to an immune cell and a cancer cell, or just to a cancer cell, and activate the immune system against the cancer cells. The novel binding reagents are designed to act, among others, as potent immune cell activators/immune checkpoint inhibitors without the toxicity of current checkpoint inhibitors. The expected effect is a highly targeted therapy envisioned to selectively destroy cancer cells without affecting normal (non-cancerous) cells. This may mean less severe side effects for the treated cancer patients compared to alternative therapies. The Company cautions that these novel therapeutics are still under early-stage research and development and is not making any express or implied claims as to their success in cancer treatment or commercial viability. The patent application seeks protection for, among others, the design of new therapeutics and methods for their use.

Keep reading... Show less
OTC:BCTXF

BriaCell Files New Provisional Patent Application for Antibody-Based Treatment of Infectious Diseases

BriaCell Therapeutics Corp. (“BriaCell” or the “Company”) (TSXV:BCT) (OTCQB:BCTXF), a clinical-stage biotechnology company specializing in targeted immunotherapy for advanced breast cancer, announces that it has filed a provisional patent application with the U.S. Patent and Trademark Office (USPTO) outlining the development and use of certain antibodies for the treatment of cancer and infectious diseases. The infectious diseases include Coronavirus Disease 2019 (COVID-19) caused by the SARS-CoV-2 virus.

The patent application, entitled “COMPUTER-GUIDED DESIGN OF ANTIBODIES INCLUDING NEUTRALIZING SARS-CoV-2 BINDING AGENTS”, outlines compositions and methods for generating antibodies to neutralize SARS-CoV-2 (the coronavirus causing COVID-19) using computer-based simulation technology. Such antibodies are envisioned to prevent and treat the life-threatening symptoms of COVID-19. The use of computer simulation creates highly targeted antibodies by improving pre-existing antibodies. The improvements include, but are not limited to, creating higher affinity and/or specificity antibodies to the SARS-CoV-2 Spike protein (the protein which the virus uses to infect cells) versus the unmodified antibody. The resulting therapeutic antibodies are expected to quickly and specifically recognize the SARS-CoV-2 virus, bind to it, and neutralize it. The patent application also provides compositions and methods, using similar technologies, for cancer-directed antibodies.

Keep reading... Show less
BioHarvest Sciences Inc. Projects 2022 Revenue to Grow 2.5X-3.5X to a Range of USD $5M-$7M

BioHarvest Sciences Inc. Projects 2022 Revenue to Grow 2.5X-3.5X to a Range of USD $5M-$7M

  • 2022 Revenue will include sales of VINIA® and Cannabis, both with high gross margins
  • Major investments in the BioFarming platform and Intellectual property
  • New patent application covers a 700% increase in Bioreactor production output

BioHarvest Sciences Inc. (CSE: BHSC) ("BioHarvest" or "the Company") announces that following the successful over-delivery of revenue targets versus guidance provided in 2021, the Company is estimating 2022 revenue to be between USD $5M-$7M, representing a significant growth of 2.5X-3.5X over 2021. The range in guidance is due to two primary determinants; the speed in which the biological technology transfer to its new 20 Tonyear facility is completed, and regulatory timelines influencing the conversion of the existing 2 Tonsyear facility from VINIA to the production of Cannabis.

The Company is also projecting to achieve break-even cash flow in 2023, when the business reaches its first scaling point. For 2022, BioHarvest plans to continue to invest heavily in R&D (as a percentage of total revenue) and in the building of manufacturing capacity for its Cannabis vertical in Israel and abroad.

Keep reading... Show less

Gilead Announces Partial Clinical Hold for Studies Evaluating Magrolimab in Combination With Azacitidine

-- Enrolled Patients in These Studies May Continue Receiving Study Medicine --

-- Studies Outside of Combination with Azacitidine Unaffected --

Keep reading... Show less
Komo Plant Based Foods to be Available for Online Purchase Across the United States through GTFO It's Vegan

Komo Plant Based Foods to be Available for Online Purchase Across the United States through GTFO It's Vegan

Komo Plant Based Foods Inc. (CSE:YUM)(OTCQB:KOMOF)(FRA:9HB) ("Komo"), a premium plant-based food company, is pleased to announce that it will soon be available for order online throughout the United States through GTFO It's Vegan, a progressive online vegan market serving consumers across the U.S

Komo received a purchase order from GTFO and plans to ship its first pallet of Komo plant-based comfort foods to GTFO headquarters in California this week. Consumers across the United States will soon be able to order, for home delivery, all of Komo's frozen products online at GTFO It's Vegan.

Keep reading... Show less
George Ragogna Appointed CFO

George Ragogna Appointed CFO

Naturally Splendid Enterprises Ltd. ("Naturally Splendid", "NSE" or "the Company") (FRANKFURT:50N)(TSXV:NSP)(OTC PINK:NSPDF) is pleased to announce that Mr. George Ragogna has been appointed Chief Financial Officer (CFO), replacing current Chief Financial Officer (CFO), Mr. Bryan Carson

Mr. Ragogna has over 30 years of experience in the Canadian financial services industry with over 20 years in a progressive leadership role specializing in; strategic planning, corporate sales, workforce optimization and regulatory compliance for the Co-operators Group Limited, a leading Canadian multi-line insurance and financial services co-operative with $56.4 billion in assets under management.

Keep reading... Show less

Allergan Aesthetics Announces Open Casting Call for BOTOX® Cosmetic

Allergan Aesthetics, an ABBVie company (NYSE: ABBV) announced today it will be hosting an open casting call seeking people who would like to share their BOTOX ® Cosmetic Story. The company continues its commitment to showcase real people and real stories as part of its larger mission to create a more inclusive and authentic dialogue around the decision to receive aesthetic treatments. Building on the success of the original ' See Yourself ' campaign launched in 2021, BOTOX ® Cosmetic, is launching its first ever open-casting call which will bring together new and existing patients to share their personal stories and treatment journeys in a national advertising campaign.

"We continue to be inspired by the individuals who use our products. We know that everyone has their own unique reason for receiving BOTOX ® Cosmetic, and we want those authentic faces and voices to be a part of our campaign," said Carrie Strom , President, Global Allergan Aesthetics and Senior Vice President, AbbVie. "Our goal is for people to see others like them and be empowered by their lives and their decisions. 'See Yourself' demystifies treatment, encourages transparency, and reflects our consumers in all of their beautiful forms, genders, and colors."

Keep reading... Show less

FDA Approves Veklury® for the Treatment of Non-Hospitalized Patients at High Risk for COVID-19 Disease Progression

-- Approval Based on Phase 3 Data Showing Veklury Significantly Reduced Risk of Hospitalization By 87% Compared with Placebo --

-- NIH Guidelines Recommend Veklury for the Treatment of Non-Hospitalized Patients at High Risk --

Keep reading... Show less

Latest Press Releases

Related News

×